Michael Burkes Brophy Sells 5,218 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA – Get Rating) CFO Michael Burkes Brophy sold 5,218 shares of Natera stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $48.94, for a total transaction of $255,368.92. Following the completion of the sale, the chief financial officer now owns 62,764 shares of the company’s stock, valued at approximately $3,071,670.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, February 1st, Michael Burkes Brophy sold 19,326 shares of Natera stock. The shares were sold at an average price of $43.68, for a total transaction of $844,159.68.
• On Monday, January 30th, Michael Burkes Brophy sold 48,697 shares of Natera stock. The shares were sold at an average price of $42.08, for a total transaction of $2,049,169.76.
• On Monday, January 23rd, Michael Burkes Brophy sold 2,273 shares of Natera stock. The shares were sold at an average price of $41.56, for a total transaction of $94,465.88.
• On Tuesday, January 3rd, Michael Burkes Brophy sold 3,644 shares of Natera stock. The shares were sold at an average price of $39.55, for a total transaction of $144,120.20.
• On Wednesday, December 28th, Michael Burkes Brophy sold 915 shares of Natera stock. The shares were sold at an average price of $39.84, for a total transaction of $36,453.60.
• On Friday, December 23rd, Michael Burkes Brophy sold 429 shares of Natera stock. The shares were sold at an average price of $42.30, for a total transaction of $18,146.70.

Natera Stock Performance

NTRA opened at $56.47 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.95 and a current ratio of 3.10. The company’s fifty day moving average price is $43.10 and its two-hundred day moving average price is $43.80. Natera, Inc. has a 1-year low of $26.10 and a 1-year high of $63.65.

Natera (NASDAQ:NTRA – Get Rating) last released its quarterly earnings data on Tuesday, February 28th. The medical research company reported ($1.37) EPS for the quarter, beating the consensus estimate of ($1.40) by $0.03. The business had revenue of $217.30 million for the quarter, compared to the consensus estimate of $215.50 million. Natera had a negative net margin of 66.79% and a negative return on equity of 121.87%. The company’s revenue was up 25.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.48) earnings per share. As a group, equities research analysts expect that Natera, Inc. will post -4.52 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its holdings in Natera by 6.7% in the first quarter. Bank of New York Mellon Corp now owns 820,974 shares of the medical research company’s stock valued at $33,399,000 after acquiring an additional 51,791 shares in the last quarter. US Bancorp DE increased its holdings in Natera by 20.0% in the 1st quarter. US Bancorp DE now owns 16,180 shares of the medical research company’s stock worth $658,000 after buying an additional 2,698 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Natera by 215.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,049 shares of the medical research company’s stock valued at $83,000 after purchasing an additional 1,399 shares during the period. Bank of Montreal Can grew its stake in shares of Natera by 80.6% during the 1st quarter. Bank of Montreal Can now owns 130,062 shares of the medical research company’s stock valued at $5,390,000 after acquiring an additional 58,049 shares during the period. Finally, MetLife Investment Management LLC bought a new position in shares of Natera during the 1st quarter valued at approximately $209,000. Institutional investors own 93.81% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on NTRA. Piper Sandler lifted their price target on shares of Natera from $70.00 to $80.00 in a report on Friday, February 17th. Raymond James raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $58.00 price target on the stock in a report on Wednesday, January 18th. Morgan Stanley lifted their price target on shares of Natera from $70.00 to $72.00 and gave the company an “overweight” rating in a report on Thursday. BTIG Research decreased their price target on shares of Natera from $95.00 to $75.00 in a report on Wednesday, November 9th. Finally, Stephens decreased their price target on shares of Natera to $67.00 in a report on Wednesday, November 16th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $78.36.

About Natera

(Get Rating)

Natera, Inc is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).